Results 291 to 300 of about 332,229 (308)
Some of the next articles are maybe not open access.
Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin–Resistant Kawasaki Disease
Arthritis & Rheumatology, 2020Anakinra has been shown to be successful in preventing and treating cardiovascular lesions both in experimental murine models of Kawasaki disease (KD) and in several studies on intravenous immunoglobulin (IVIG)– and steroid‐resistant patients with KD ...
I. Koné-Paut +13 more
semanticscholar +1 more source
The Lancet, 2019
BACKGROUND Genetic studies have indicated possible involvement of the upregulated calcium-nuclear factor of activated T cells pathway in the pathogenesis of Kawasaki disease.
H. Hamada +71 more
semanticscholar +1 more source
BACKGROUND Genetic studies have indicated possible involvement of the upregulated calcium-nuclear factor of activated T cells pathway in the pathogenesis of Kawasaki disease.
H. Hamada +71 more
semanticscholar +1 more source
Rheumatic Disease Clinics of North America, 2015
Kawasaki disease (KD) is the archetypal pediatric vasculitis, exemplifying the unique aspects and challenges of vascular inflammation in children. The condition is almost unheard of in adults, is closely associated with infections, and is self-limited, with fever resolving after an average of 12 days even without treatment. Yet KD is also a potentially
openaire +2 more sources
Kawasaki disease (KD) is the archetypal pediatric vasculitis, exemplifying the unique aspects and challenges of vascular inflammation in children. The condition is almost unheard of in adults, is closely associated with infections, and is self-limited, with fever resolving after an average of 12 days even without treatment. Yet KD is also a potentially
openaire +2 more sources
Heart and Vessels, 1985
Kawasaki disease, a pathologic syndrome known to occur in children, was first described in 1967 as mucocutaneous lymph node syndrome by Kawasaki. The disease occurs chiefly in infants under 4 years of age, presenting with symptoms similar to scarlet fever or Stevens-Johnson syndrome. The changes are found at postmortem and consist of multiple aneurysms
openaire +2 more sources
Kawasaki disease, a pathologic syndrome known to occur in children, was first described in 1967 as mucocutaneous lymph node syndrome by Kawasaki. The disease occurs chiefly in infants under 4 years of age, presenting with symptoms similar to scarlet fever or Stevens-Johnson syndrome. The changes are found at postmortem and consist of multiple aneurysms
openaire +2 more sources
Pediatrics In Review, 1996
Kawasaki syndrome (KS) is an acute, febrile, self-limited, multisystem vasculitis that almost exclusively affects young children. First described in 1967 by Dr. Tomisaku Kawasaki of Tokyo, Japan, it now has been recognized as occurring in all regions of the world among children of multiple and diverse ethnic groups.
openaire +2 more sources
Kawasaki syndrome (KS) is an acute, febrile, self-limited, multisystem vasculitis that almost exclusively affects young children. First described in 1967 by Dr. Tomisaku Kawasaki of Tokyo, Japan, it now has been recognized as occurring in all regions of the world among children of multiple and diverse ethnic groups.
openaire +2 more sources
Platelets in Kawasaki disease: mediators of vascular inflammation
Nature Reviews RheumatologyMagali Noval Rivas +3 more
semanticscholar +1 more source
Kawasaki disease. Kawasaki disease?
Alaska medicine, 2000Four cases of Kawasaki Disease (KD) treated at Bartlett Regional Hospital, Juneau, AK, are reviewed and discussed. Diagnostic and therapeutic measures recommended by the American Heart Association were followed and these cases discussed. Another case of probable Kawasaki Disease occurring in Anchorage, Alaska Native Medical Center, in 1965, is ...
openaire +1 more source